How do I set a price alert for ENTA?

To set a ENTA price alert on Stock Alarm Pro, navigate to the ENTA quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for ENTA?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for ENTA. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for ENTA?

Stock Alarm Pro supports over 125 trigger types for ENTA: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about ENTA price changes?

ENTA alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for ENTA alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for ENTA and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

Enanta Pharmaceuticals, Inc.(ENTA)

$12.84—

WatchlistAsk AI Chart

Enanta Pharmaceuticals, Inc.(ENTA)

NASDAQAbout this data

$12.84—

WatchlistAsk AI Chart Studio

ENTA(ENTA)

ENTA

10/2/26

Enanta Pharmaceuticals (ENTA)

Friday

4:13 AM

ThesisEnanta Pharmaceuticals: the risks are mounting — HCV market maturation and generic competition eroding Mavyret royalty base (primary current revenue source)…

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$65M	$65M	$60M
Rev. Growth	-3.4%	-0.9%	-6.7%
EPS	$-3.84	$-2.29	$-2.20
EPS Growth	+29.9%	+40.3%	+4.1%
P/E	—	—	—

★ Analysts see FY2026 revenue reaching $65M — -0.9% growth in a single year.

What Could Go Wrong

01HCV market maturation and generic competition eroding Mavyret royalty base (primary current revenue source), with limited visibility on replacement revenue streams until pipeline assets reach commercialization
02Clinical trial failure risk inherent to drug development - Phase 2/3 programs have 30-50% historical success rates in antiviral/NASH indications, with binary outcomes creating significant valuation volatility
03Regulatory pathway uncertainty for novel antiviral mechanisms and NASH endpoints, with FDA guidance evolving and potential for additional trial requirements or safety concerns
04RSV antiviral space increasingly crowded with GSK/Pfizer vaccines approved and other antivirals in development (Roche, AstraZeneca partnerships), requiring clear differentiation in efficacy, safety, or convenience
05NASH drug development highly competitive with multiple mechanisms in late-stage trials (Madrigal, Akero, Viking) and risk of being out-positioned by earlier approvals or superior data
06Dependence on partnership strategy exposes company to large pharma priorities and capital allocation decisions - partners may deprioritize programs or renegotiate terms
07Cash burn of $30-40M annually with $130M+ cash balance provides approximately 3-4 year runway, but major clinical programs require additional financing before potential commercialization or partnership
08Equity dilution risk from future capital raises if pipeline milestones delayed or partnership terms unfavorable - current $300M market cap limits financing flexibility without significant shareholder dilution

FY2025 Snapshot

Revenue: $65M
Rev. Growth: -3.4%
Gross Margin: 93.0%
Op. Margin: -131%
Net Margin: -125%
Net Income: $-82M
NI Growth: +29.4%
EPS: $-3.84
1Y Return: +7.3%

ENTA Chart

My Notes

growth/speculative - Attracts biotech-focused investors seeking asymmetric risk/reward from clinical catalysts and partnership optionality.
Rising interest rates negatively impact valuation multiples for pre-revenue biotech stocks as discount rates increase for future cash flows…
Watch on earnings: Mavyret quarterly royalty revenue and year-over-year decline rate (proxy for HCV market erosion), Clinical trial enrollment completion rates and data readout timelines for EDP-323 (RSV) and EDP-305 (NASH), Cash and marketable securities balance vs quarterly operating cash burn (runway to key milestones).

One Sentence Summary:

The bear case: hcv market maturation and generic competition eroding mavyret royalty base (primary current revenue source).

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E

—

What Could Go Wrong

01HCV market maturation and generic competition eroding Mavyret royalty base (primary current revenue source), with limited visibility on replacement revenue streams until pipeline assets reach commercialization

02Clinical trial failure risk inherent to drug development - Phase 2/3 programs have 30-50% historical success rates in antiviral/NASH indications, with binary outcomes creating significant valuation volatility

03Regulatory pathway uncertainty for novel antiviral mechanisms and NASH endpoints, with FDA guidance evolving and potential for additional trial requirements or safety concerns

04RSV antiviral space increasingly crowded with GSK/Pfizer vaccines approved and other antivirals in development (Roche, AstraZeneca partnerships), requiring clear differentiation in efficacy, safety, or convenience

05NASH drug development highly competitive with multiple mechanisms in late-stage trials (Madrigal, Akero, Viking) and risk of being out-positioned by earlier approvals or superior data

06Dependence on partnership strategy exposes company to large pharma priorities and capital allocation decisions - partners may deprioritize programs or renegotiate terms

07Cash burn of $30-40M annually with $130M+ cash balance provides approximately 3-4 year runway, but major clinical programs require additional financing before potential commercialization or partnership

08Equity dilution risk from future capital raises if pipeline milestones delayed or partnership terms unfavorable - current $300M market cap limits financing flexibility without significant shareholder dilution

My Notes

growth/speculative - Attracts biotech-focused investors seeking asymmetric risk/reward from clinical catalysts and partnership optionality.

Rising interest rates negatively impact valuation multiples for pre-revenue biotech stocks as discount rates increase for future cash flows…

Watch on earnings: Mavyret quarterly royalty revenue and year-over-year decline rate (proxy for HCV market erosion), Clinical trial enrollment completion rates and data readout timelines for EDP-323 (RSV) and EDP-305 (NASH), Cash and marketable securities balance vs quarterly operating cash burn (runway to key milestones).